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THE ESTIMATED IMPACT OF IN VITRO BIOMARKERS ON THE COST-
EFFECTIVENESS OF POPULATION-WIDE COLORECTAL CANCER 
SCREENING
Wittenberg GM, Noy K, Dejori M, Fasulo D
Siemens Corporate Research, Princeton, NJ, USA
OBJECTIVES: Most screening options for colorectal cancer (CRC) are invasive and
patient compliance in population wide screening programs is low. Recently, potential
candidates for blood-based biomarker tests for early cancer detection have been
described. Here we perform an extensive cost-effectiveness analysis of integrated 
diagnostic screening workﬂ ows to determine the anticipated impact of incorporating 
two candidate in vitro biomarkers, CCSA-3 immunoassay and SEPT9 epigenetics
testing, on both patient mortality and medical costs. METHODS: Markov Cycle
Tree models were constructed to simulate disease progression and screening for 4
million people, representative of the U.S. population, aging from 50 to 80. Eight 
workﬂ ows were constructed from combinations of Optical Colonoscopy (OC), CT 
Colonography (CTC), Fecal Occult Blood Test (FOBT), Immunoassay (CCSA-3), and
Epigenetics (SEPT9). Kernel density estimation was performed on raw biomarker data 
to generate disease-state probability distributions of biomarker levels for sensitivity 
and speciﬁ city calculations. Finally, we perform sensitivity analysis on the sensitivity 
and speciﬁ city of a generic in vitro diagnostic test. RESULTS: CRC screening work-
ﬂ ows that include initial screening with inexpensive in vitro diagnostic tests given every 
3 years outperform others in both cost and effectiveness. Incremental costs compared 
with No Screening are as follows: OC $1.4B increase, SEPT9 $582M increase, CCSA-
3 $2.8B decrease. Life-years saved: OC 78,535, SEPT9 185,839, CCSA-3 216,434. 
Despite having lower sensitivity and speciﬁ city, the low-cost and minimally-invasive 
nature of these tests allow more frequent screening, resulting in better detection of 
early stage disease than with OC alone. CONCLUSIONS: Though currently there are
no blood-based biomarkers approved for early colorectal cancer screening, we can 
assess the expected impact of these tests once developed on colorectal cancer in the 
U.S. population. A complete sensitivity analysis of the sensitivity and speciﬁ city of a
hypothetical biomarker provides a map of cost-effectiveness within which any test
developed will fall.
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AN ECONOMIC EVALUATION OF CIRCULATING TUMOR CELLS
DETECTION IN METASTATIC BREAST CANCER
Rahman M1, Malone D2, Armstrong E2
1Ortho Clinical Diagnostics, Raritan, NJ, USA, 2University of Arizona, Tucson, AZ, USA
OBJECTIVES: Metastatic breast cancer (MBC) is a costly and burdensome disease in 
the United States. In 2008, an estimated 182,460 women will receive a new diagnosis
of breast cancer and 40,480 will die from the disease. The objective of this study was
to conduct a cost-effectiveness analysis of a diagnostic test for circulating tumor cells
(CTC) (CellSearch) plus imaging versus imaging alone. METHODS: This study used 
a probabilistic Markov cost-utility analysis based on a pivotal clinical trial evaluating 
the CellSearch technology. The perspective of the study was that of a managed care 
organization. The primary basis for estimates of transitions between health states were 
derived from the pivotal trial evaluating CellSearch. Using patient level data, transi-
tion probabilities were developed for patients with CTC counts of  5 or q5 over 3 
month intervals. The same approach was used for imaging studies where imaging was
classiﬁ ed as either regression or stable disease or progressive disease. Utility estimates
were obtained from the literature. The model took into account estrogen/progesterone 
receptor status as well as HER2 receptor status. Costs were based on Medicare fee
schedules or those reported in the literature. RESULTS: The mean number of Quality
Adjusted Life Years (QALYs) for imaging was 13.60 (SD  1.88) as compared to 15.32
(SD  1.44) for CellSearch plus imaging (p  0.05). The annualized treatment and
monitoring costs of using CellSearch plus imaging was higher than imaging alone 
($56,392 vs. $44,408, p  0.05). Cost-effectiveness acceptability curves indicated that 
CellSearch plus imaging had a higher probability of being cost-effective than imaging 
alone when willingness to pay per QALY exceeded $7,500. CONCLUSIONS: This
analysis suggests that CellSearch combined with imaging may be a cost-effective 
strategy for monitoring patients with MBC. The additional cost of the technology 
relative to the additional gains in QALYs falls well below commonly cited thresholds
for accepting new technologies.
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COST-EFFECTIVENES ANALYSIS OF DOCETAXEL VERSUS
STANDARD REGIMEN AS THE INDUCTION CHEMOTHERAPY 
OF LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL
CARCINOMA IN POLAND
Walczak J1, Lasota K1, Malczak I1, Pawlik D1, Semeniuk A1, Simon A1, Bryl M1, Lis J2, Nogas G1
1Arcana Institute, Cracow, Poland, 2Sanoﬁ  – Aventis sp. z o.o, Warsaw, Poland
OBJECTIVES: To conduct a cost effectiveness analysis (CEA) of docetaxel plus cis-
plastin and 5-ﬂ uorouracil (TPF) vs cisplastin and 5-ﬂ uorouracil (PF) as induction
chemotherapy followed by concurrent chemoradiation (RCT TAX 324) or radiation
therapy (RCT TAX 323) in locally advanced unresectable head and neck squamous 
cell carcinoma (HNSCC) in Poland. METHODS: We constructed two cost-effective-
ness Markov models (basing on TAX 324 or TAX 323) which include four health
states: stable, response, progression and death. The CEA was conducted from both
payers’ perspective (National Health Fund and patient), using clinical data from pub-
lished sources, Polish cost data and a 15-year time horizon and annual discount rate
of costs and beneﬁ ts at 5%. RESULTS: Based on a systematic review two randomized
clinical trials were included in the comparison TAX 323 and TAX 324. Average costs 
of the treatment for HNSCC (including chemotherapy, radiation or chemoradiation
therapy, treatment of serious adverse events, surgery, health state monitoring, relapse 
treatment and palliative care) were: PLN54,708 for TPF and PLN40,614 for PF basing 
on TAX 324 and PLN46,107 for TPF and PLN27,510 for PF basing on TAX 323.
Basing on TAX 324 treatment effects (per patient) were 4.3631 LYG vs. 3.4183 LYG 
respectively for TPF and PF regimens. Basing on TAX 323 treatment effects (per 
patient) were 1.9694 LYG for TPF vs. 1.6875 LYG for PF. ICER for the TPF vs. PF
comparison for trial TAX 324 was PLN14,916.40/LYG and PLN65,958.51/LYG for
trial TAX 323. CONCLUSIONS: The docetaxel regimen is more effective and more
expensive in the induction treatment of patients with locally advanced unresectable 
HNSCC compared with PF chemotherapy. ICERs are below the acceptable threshold, 
therefore the docetaxel therapy can be considered a cost-effective treatment for locally 
advanced unresectable HNSCC in Poland.
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COST-EFFECTIVENESS ANALYSIS OF LUNG CANCER SCREENING 
WITH COMPUTED TOMOGRAPHY
Chien CR1, Chen THH2
1China Medical University Hospital, Taichung, Taiwan, 2National Taiwan University Hospital, 
Taipei, Taiwan
OBJECTIVES: Given a high cost again high incidence of lung cancer lung cancer 
screening with Computed Tomography (CT) is a debatable issue within medical com-
munity. METHODS: We performed a health economic analysis via computer simula-
tion to track the annual transition among ﬁ ve health states (disease free, preclinical 
disease, local disease with treatment, advanced lung cancer, and death) with a proba-
bilistic Markov model. The primary scenario mimics that of the Dutch-Belgian ran-
domised lung cancer multi-slice CT screening trial (NELSON) study. The primary
endpoint was the incremental cost- effectiveness and cost-utility (quality-adjusted life 
year, QALY) ratio (ICER and ICUR). Model parameters were derived from literatures. 
Model validation on stage-speciﬁ c case ﬁ nding, survival rate, and treatment related
cost were simulated and compared with literatures. RESULTS: Model validation 
revealed comparable results between estimation and observation. In our primary sce-
nario, the mean ICER was 51,774 USD/LY. If 50,000 USD/LY was taken as the 
threshold of willingness to pay, there was 48% or so chance that CT screening will 
be cost-effective. When quality-of-life related health utility was taken into consider-
ation, the mean ICUR was 730,966 (USD/QALY). When other screening schedules
were simulated and compared, intensive screening (such as annual screening) is no 
cost-effective. CONCLUSIONS: Our simulation reveals that population-based lung 
cancer screening with CT is not cost -effective. This result provides an evidence for 
policy-makers on lung cancer screening before the results of randomized controlled 
studies available.
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A COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE AT 
A TERTIARY CANCER CENTER
Miller LA, Lau J, Lal LS, Dacosta Byﬁ eld S, Arbuckle R
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
OBJECTIVES: This study evaluates the cost-effectiveness and budget impact of benda-
mustine, a recently approved alkylating mechlorethamine derivative for the treatment
of chronic lymphocytic leukemia (CLL), as part of the Formulary Management System
at a major tertiary cancer center in the United States. METHODS: Decision analytical 
models were developed to estimate the cost-effectiveness of bendamustine in CLL
patients receiving either ﬁ rst-line or salvage therapy. The ﬁ rst-line model compared 
bendamustine alone versus a combination therapy of ﬂ udarabine, cyclophosphamide,
and rituximab (FCR). The salvage model also compared bendamustine alone to the
same FCR combination for CLL therapy. The outcome of interest was progression-free
life years (PFLY), based on published literature and clinical use estimates. Direct
institutional medical costs for a one-year time period were utilized. In addition, a 
budget impact analysis was also conducted for adding bendamustine to the Formulary. 
RESULTS: Bendamustine is more convenient – only a single infusion is required 
compared to multiple infusions for the FCR combination. However, based on outcome 
estimates from literature and the application of the institutional costs, bendamustine
was found to be less costly and also less effective. The cost per PFLY saved by using
the FCR combination for treatment of CLL for ﬁ rst-line therapy was $2964. The cost 
was $5553 per PFLY saved for the same FCR combination for the treatment of CLL 
in salvage therapy. The budget impact model showed that the institution will utilize 
about $6.43 million worth of bendamustine annually based on acquisition costs and 
estimated usage. CONCLUSIONS: Bendamustine appears to be less cost-effective than 
other therapeutic regimens for the treatment of CLL. Bendamustine was added to the 
Formulary as a second- or third-line option for both model indications. Future eco-
nomic analyses will be conducted to determine how closely the current economic
model predicts actual utilization and cost-effectiveness at the institution.
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EVIDENCE SYNTHESIS FOR MODELING THE NATURAL HISTORY OF 
ANAL PENILE AND OROPAHRYNGEAL CANCERS
Abimbola T, Craig BM, Rollison D, Kumar A, Giuliano A
Mofﬁ tt Cancer Center, Tampa, FL, USA
OBJECTIVES: Substantial evidence on the increased incidence of HPV-associated 
malignancies is mounting as a result of on-going natural history studies on HPV 
infections as well as vaccination trials. Yet, there remains a paucity of results from
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longitudinal studies on the natural history of anal, penile, and oropharyngeal cancers.
The objective of this paper is the synthesis of the totality of evidence on anal, penile, 
and oropharyngeal cancers for the purpose of parameterizing decision analytic 
modeling. Following the known natural history of cervical carcinogenesis, our goal is 
to estimate the rates of transition from HPV infection to precancer, the rate of 
precancer clearance, and the rate of progression of precancer to cancer. METHODS:
We conducted a systematic review of the literature to identify all articles with longitu-
dinal data on the natural history of anal, penile, and oropharyngeal cancers. Including 
those studies that report quantiﬁ able evidence, we conduct a meta-analysis on the 
core parameters. The review was performed as per the methods recommended by 
the Cochrane Collaboration. RESULTS: Using PubMed, we identiﬁ ed 605 articles rel-
evant to the anal site, 540 articles for the penile site, and 267 on the oropharyngeal 
site. However, systematic review resulted in only 9 studies, all of which pertained to
anal precancer/cancer. Given the available data, we estimated the annual rates of pre-
cancer clearance and progression to be 11.4% (8.34%, 14.55%) and 2.18% (0.92%, 
3.47%), respectively. CONCLUSIONS: Decision analytic models provide a frame-
work for formulation of vaccination policies, incorporating all available evidence. This
review summarizes the totality of evidence on HPV and these three cancers to inform
health policy, speciﬁ cally policies concerning male vaccination against papillomavirus
(MVP).
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BUDGETARY IMPACT OF METASTATIC RENAL CELL CARCINOMA
(MRCC) TREATMENT ON THE COLOMBIAN GENERAL HEALTH SOCIAL
SECURITY SYSTEM (SGSSS)
Cardona AF1, Caceres HA2, Spath A2, Lujan M3, Lopera D4, Otero JM5, Carranza H6, 
Godoy JI7
1Catalan Institute of Oncology – Hospital Germans Trias i Pujol, Barcelona, Spain, 2Pﬁ zer S.A, 
Bogotá D.C, Colombia, 3Instituto de Cancerología – Clínica Las Américas – Universidad 
Pontiﬁ cia Bolivariana, Medellín, NA, Colombia, 4Oncólogos de Occidente, Manizales, NA, 
Colombia, 5Foundation for Clinical and Molecular Cancer Research (FICMAC), Bogotá, NA, 
Colombia, 6Fundación Santa Fe de Bogotá, Bogotá, NA, Colombia, 7Hospital Militar Central, 
Bogotá DC, Colombia
OBJECTIVES: Medical treatment for mRCC during 2002 represented around 4% of 
the resources designed for cancer treatment in Colombia; a local study has shown that
Sunitinib (SU) was the most cost-effective medication for ﬁ rst-line treatment of mRCC. 
We evaluated the budgetary impact of including SU as choice for ﬁ rst-line treatment
of mRCC compared to the current treatment being offered in Colombia (Interferon-á
(IFN), BevacizumabIFN and Sorafenib). METHODS: Sunitinib’s budgetary impact 
was estimated including mRCC patients which were candidates to receive ﬁ rst-line 
treatment under the SGSSS, using a 5-year time horizon. A Markov model was devel-
oped to predict costs simulating disease progression. Data regarding frequency of use
and health service cost units consumed was taken from a series of 24 patients treated
in four different cities. Service costs corresponded to the average value billed by the 
HMOs, calculated from 33 sources of information which were representative of the
country’s market. The 5-year projected proﬁ le for the current treatment of patients
suffering from mRCC was estimated starting from each medication’s market share 
and then compared to a scenario of changing Sunitinib’s share to being 100%. The
measures of effectiveness applicable for the projection were taken from previously-
published clinical trials. A One-way sensitivity analysis was conducted for validating
the model’s robustness and costs are shown in Colombian pesos (Col$) (Exchange rate 
1 USD  1966.26 Col$). RESULTS: The total budgetary impact of SU as ﬁ rst-line
treatment for mRCC represented a saving for the Colombian SGSSS of Col$
2,038,197,489 during 2009, Col$ 2,215,421,548 in 2010, Col$ 2,068,559,499 in 
2011, Col$ 1,923,678,137 in 2012 and Col$ 1,840,110,375 in 2013. This would 
represent an overall saving of Col$ 10,085,967,048 for the next 5-years. CONCLU-
SIONS: Including SU as the option of choice for ﬁ rst-line treatment of mRCC in the 
Colombian SGSSS would be favorable and cost-saving.
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THE COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS DNA 
TESTING FOR CERVICAL CANCER: A SYSTEMATIC REVIEW OF THE
LITERATURE
Kingston-Riechers J
Institute of Health Economics, Edmonton, AB, Canada
OBJECTIVES: To assess the current literature on the cost-effectiveness of HPV DNA 
testing (HPVt) a) as an alternative to conventional cytology and b) to triage equivocal
cytology results. METHODS: Studies are included if they provide cost-effectiveness 
ﬁ gures for HPVt in relation to no screening or conventional cytology, are in English, 
based on a sample drawn from a developed market economy and were published after
2002. RESULTS: Eleven articles matching the search criterion were found. Though
time horizons and costs that are included vary, HPVt is generally found to be cost-
effective for older women. Based on a ﬁ ve year screening interval, using HPV DNA 
testing to triage atypical squamous cells of undetermined signiﬁ cance is estimated to
cost between about $2,900 to $33,000 per life year saved. CONCLUSIONS: HPVt 
may be a cost-effective screening tool for cervical cancer.
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PHARMACOECONOMICAL ASPECT OF ONCOLOGICAL THERAPY
Dubajova V1, Foltán V1, Tomek D2, Dubaj M3
1Comenius University, Bratislava, Slovak Republic, 2Slovak Society for Pharmacoeconomics, 
Bratislava, Slovak Republic, 3University Hospital, Nitra, Slovak Republic
OBJECTIVES: In current era the costs of the health keeping are increasing, therefore
the pharmacoeconomic has determing role. Analysis includes all stages of health 
keeping , but spotlights are drug costs. Selection of drugs according general criteria 
helps to save public ﬁ nance and allows it better utilization. METHODS: Valuation of 
utilization of drugs in oncological practice is based on data from the State Institute 
for Drug Control in Slovakia which have been evaluated for time period 10 years.
Data from the Public Health Insurance, which consist of drug costs, costs on diagnostic 
and therapy of oncological diseases, are attached to the former data. RESULTS: Public 
Health Insurance invested €0.19 mld on the therapy of the patients with oncological 
disease, which presented 10% from all costs on health keeping. Drugs represented
about 38% , hospitalization represented 28%, costs of diagnostic represented 15%
and ambulation health keeping represented 14%. But costs on ambulation health 
keeping have increased more than 28%, drug costs more than 15% and diagnostic 
costs more than 13%. According these data the most expensive diagnosis are breast 
cancer, colorectal cancer and the cancer of lungs. CONCLUSIONS: Health Insurances 
as ﬁ nancial institutions play the most important role in payment of complex therapy
of oncological patients. Because of new technology on diagnostic and therapy in 
oncology, economic value of costs is increasing. Costs of modern oncological therapy 
per one patient are more than approximately €1000.
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PHARMACOECONOMIC EVALUATION OF THE USE OF SOMATOSTATIN
ANALOGS HANDLING THE ASSOCIATED SYMPTOMS OF CARCINOID 
SYNDROME
Salinas EG, Idrovo J, Zapata L
Guia Mark, Mexico, DF, Mexico
OBJECTIVES: There is a group of neoplasia that secretes vasoactive peptides causing
carcinoid syndrome. Surgical treatment is the election, however, if after surgery a
residual tumor is maintained, the use of somatostatin analogs: lanreotide Autogel y 
octreotide, is the treatment to follow. The objective of this research paper is to evaluate
which of the somatostatin analogs is the most effective in the symptomatic control of 
carcinoid syndrome, associated with the lowest cost. METHODS: Cost minimization
analysis from an institutional perspective was estimated, considering only direct
medical costs for a one year temporary horizon, using a decision tree model. Univariate 
sensitivity and probability analysis was carried out for this purpose. Costs were esti-
mated using prices of 2008 and are expressed in US dollars (exchange rate of 11.14
pesos/ 1 US dollar). RESULTS: According to the model, 41.3% of patients would
achieve control of their symptomatology either with Lanreotide Autogel, as with
octreotide, when adjusting the reported efﬁ cacy in the literature by the survival rate 
of one year for this illness. Treatment with Lanreotide Autogel implies the lowest 
average cost per patient with carcinoid syndrome: $15,317.18 followed by the treat-
ment with octreotide with a cost of $19,231.42. Sensitivity analyses show that lan-
reotide would support the treatment with the lowest cost, which would make it the 
dominant treatment or at least the treatment above the efﬁ ciency line. CONCLU-
SIONS: Lanreotide Autogel is the treatment that minimizes attention cost of carci-
noid syndrome, from the institutional perspective within the Mexican context.
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PHARMACOECONOMIC EVALUATION OF SUNITINIB MALATE FOR
FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA
IN MEXICO
Tenorio C1, Vargas J2, Rizo-Rios P3, Flores-Gil O4, Martínez-Fonseca J5, Mould-Quevedo J6, 
Davila-Loaiza G6
1Instituto Nacional de Cancerología, Mexico, DF, Mexico, 2Econopharma Consulting SA de
CV, Mexico, DF, Mexico, 3Instituto Nacional de Cancerología, Mexico City, Mexico, 4ESCUELA
MÉDICO NAVAL, Mexico City, Mexico, 5Econopharma Consulting SA de CV, Mexico City, 
Mexico, 6Pﬁ zer Mexico, Mexico City, Mexico
OBJECTIVES: Metastatic Renal cell carcinoma (mRCC), the most prevalent kidney 
cancer, is a rare malignancy with a poor prognosis; fewer than 10% of patients with 
metastatic disease survive beyond 5 years. The purpose of the study was to model the
economic and health consequences of ﬁ rst-line treatments in adult patients with mRCC 
in stages III and IV from an institutional perspective. METHODS: A cost-effectiveness 
analysis was developed using a stochastic Markov modeling approach. The model 
simulates treatment costs, progression free-months (PFM) and overall survival (OS) 
in a three-year period among four possible health states (no new progression, death 
due to mRCC, history of new progression and death due to other causes). The model 
compared in a six-week cycles: sunitinib 50 mg/day vs. sorafenib, bevacizumabIFN-
alpha and IFN-alpha alone (baseline). Transition probabilities were obtained from 
previously published trials. Resource use and costs data were obtained from random-
ized hospital records at Hospital de Oncologia CMN “Siglo XXI” in Mexico City 
(n  35). Both costs and effectiveness were discounted using a 3% annual rate. One-
way and probabilistic sensitivity analyses were performed and acceptability curves 
were constructed. RESULTS: First-line treatment with sunitinib showed the highest 
PFM and OS (10.1 and 19.9 months) followed by bevacizumabIFN-alpha (9.4 and 
19.1 months); sorafenib(5.1 and 17.3 months) and IFN-alpha alone(4.72 and 16.35 
months). Expected health care costs for sunitinib in the three-year follow-up period 
resulted in US$49,181; bevacizumabIFN-alpha (US$95,363); sorafenib (US$50,265) 
